Journal
CELL METABOLISM
Volume 33, Issue 10, Pages 1926-+Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2021.06.014
Keywords
-
Categories
Funding
- Major Research plan of the National Natural Science Foundation of China [91742204]
- National Natural Science Foundation of China [81670633, 81600556, 81770681, 81974086, 81974087]
- National Natural Science Foundation of China for Young Scholars [81800608]
- National Key Research and Development Program [2016YFC0906103, 2018YFC1314000]
Ask authors/readers for more resources
The study demonstrates that oral administration of the probiotic Lactobacillus casei Zhang can correct gut microbial dysbiosis, alleviate kidney injury, and delay the progression of chronic kidney disease. By increasing levels of SCFAs and nicotinamide, L. casei Zhang shows potential as a therapy to reduce renal inflammation and slow the decline of kidney function.
The relationship between gut microbial dysbiosis and acute or chronic kidney disease (CKD) is still unclear. Here, we show that oral administration of the probiotic Lactobacillus casei Zhang (L. casei Zhang) corrected bilateral renal ischemia-reperfusion (I/R)-induced gut microbial dysbiosis, alleviated kidney injury, and delayed its progression to CKD in mice. L. casei Zhang elevated the levels of short-chain fatty acids (SCFAs) and nicotinamide in the serum and kidney, resulting in reduced renal inflammation and damage to renal tubular epithelial cells. We also performed a 1-year phase 1 placebo-controlled study of oral L. casei Zhang use (Chinese clinical trial registry, ChiCTR-INR-17013952), which was well tolerated and slowed the decline of kidney function in individuals with stage 3-5 CKD. These results show that oral administration of L. casei Zhang, by altering SCFAs and nicotinamide metabolism, is a potential therapy to mitigate kidney injury and slow the progression of renal decline.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available